Shaun A. Kirkpatrick


Shaun A. Kirkpatrick is the President, Biotechnologies of Research Corporation Technologies (RCT) in Tucson, Arizona, and serves on the company’s Board of Directors. Mr. Kirkpatrick oversees RCT’s investment portfolio and technology development and licensing activities in therapeutics, life science tools and diagnostics. RCT’s investment and technology portfolio includes some of today’s landmark platforms, pharmaceuticals and diagnostics, including the anticancer drugs cisplatin and carboplatin, the PSA blood test for prostate cancer, the technetium-99-based imaging agents, the Pichia protein expression system and the anticonvulsant drug Vimpat®. Mr. Kirkpatrick received a master’s degree in international economics from the Johns Hopkins University School of Advanced International Studies and a bachelor’s degree in economics and ecology/evolutionary biology from the University of Arizona. Mr. Kirkpatrick serves on the boards of several companies in RCT’s venture investment portfolio and is also a board member of the Flinn Foundation in Phoenix, AZ and the Critical Path Institute in Tucson, AZ.

James A. Mack


Mr. Mack retired as the Chairman and CEO of Cambrex Corp, a NYSE company focused on the life science industry. In addition to Dispersol he serves on the Board of Research Corporation Technologies a Tucson, AZ based company dedicated to funding new therapeutic and medical device commercialization. Prior to Cambrex, Mr. Mack was the V.P. of Specialty Chemicals at Olin Corp. and the President of Chemicals Division of Sherwin-Williams. He received a BS in Chemical Engineering. from Michigan Technological University and an MBA from Western New England College. Mr. Mack and his wife, Lorna, divide their time between Westport. CT and Sarasota, FL. They have five children and six grandchildren

Jeff Samberg


Jeff Samberg is the Managing Director of Acadia Woods Partners, LLC, a New York based investment partnership that focuses primarily on early stage technology companies. Jeff lived in the San Francisco Bay Area for 15 years where he held a number of high-tech management roles, including Vice President of Corporate Strategy for PeopleSoft Inc., Vice President of Business Development for Wily Technology, and Entrepreneur in Residence for Greylock Partners. Jeff received his MBA from Stanford University’s Graduate School of Business and his B.A. with high honors in Economics from Princeton University.

Gershon Yaniv


Gershon Yaniv is a co-founder and former CEO of DisperSol. Prior to DisperSol, Gershon was the CEO of IntegriCo Composites, a plastic products manufacturer. Gershon also worked at Simula Inc. (currently a BAE Systems company) for fifteen years, serving in various positions including Director of Corporate R&D, and founder and President of the Automotive Safety Division (ASD). He is an engineer by training with a PhD in Composite Materials from The Technion, Israel Institute of Technology, and an Executive MBA from Arizona State University. Gershon is the inventor of 14 US and international patents.

Edward M. Rudnic


Ed Rudnic is the CEO of DisperSol. Prior to DisperSol, he served as the CEO of QRx Pharma. Dr. Rudnic was the founder, Chairman and CEO of MiddleBrook Pharmaceuticals. Prior to founding MiddleBrook, he was the Senior Vice President, Development and Technical Operations for Shire Laboratories and held management roles at Merck (Schering-Plough) and at Bristol Myers-Squibb (E.R. Squibb). He is the lead inventor or a co-inventor of 54 issued U.S. patents, and numerous related international patents. Dr. Rudnic holds a B.S. in Pharmacy, a M.S. in Pharmaceutics, and a PhD in Pharmaceutical Sciences from the University of Rhode Island.